Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Sarah M. Talamantes"'
Autor:
Ricardo Costa, Rubens B. Costa-Filho, Sarah M. Talamantes, Fernando Queiroga Jr, Emmanuel C. Campello, Henrique Cartaxo, Rubens B. Costa
Publikováno v:
Case Reports in Oncology, Vol 10, Iss 2, Pp 524-530 (2017)
Interstitial lung disease is a rare complication of trastuzumab-based breast cancer treatment with few case reports published. Herein, we report the case of a 67-year-old female with early-stage HER2-postitive breast cancer who developed interstitial
Externí odkaz:
https://doaj.org/article/78f1c06bd00e43f5bb9cef94f9ae1d89
Autor:
Ricardo Costa, Alfred Rademaker, Benedito A. Carneiro, Corinne H. Miller, Manali Bhave, Jason B. Kaplan, Sarah M. Talamantes, Young Kwang Chae, R. Costa, Devalingam Mahalingam
Publikováno v:
Oncotarget
// Rubens Barros Costa 1 , Ricardo L.B. Costa 2 , Sarah M. Talamantes 3 , Jason B. Kaplan 1 , Manali A. Bhave 1 , Alfred Rademaker 4 , Corinne Miller 5 , Benedito A. Carneiro 6 , Devalingam Mahalingam 1 and Young Kwang Chae 1 1 Developmental Therapeu
Autor:
Ricardo Costa, Young Kwang Chae, Sarah M. Talamantes, Irene Helenoswki, Benedito A. Carneiro, R. Costa, Francis J. Giles, William J. Gradishar, Razelle Kurzrock
Publikováno v:
Oncotarget
Oncotarget, vol 8, iss 40
Costa, R; Costa, RB; Talamantes, SM; Helenoswki, I; Carneiro, BA; Chae, YK; et al.(2017). Analyses of selected safety endpoints in phase 1 and late-phase clinical trials of anti-PD-1 and PD-L1 inhibitors: prediction of immune-related toxicities.. Oncotarget, 8(40), 67782-67789. doi: 10.18632/oncotarget.18847. UC San Diego: Retrieved from: http://www.escholarship.org/uc/item/4m19p6d2
Oncotarget, vol 8, iss 40
Costa, R; Costa, RB; Talamantes, SM; Helenoswki, I; Carneiro, BA; Chae, YK; et al.(2017). Analyses of selected safety endpoints in phase 1 and late-phase clinical trials of anti-PD-1 and PD-L1 inhibitors: prediction of immune-related toxicities.. Oncotarget, 8(40), 67782-67789. doi: 10.18632/oncotarget.18847. UC San Diego: Retrieved from: http://www.escholarship.org/uc/item/4m19p6d2
// Ricardo Costa 1 , Rubens B. Costa 1 , Sarah M. Talamantes 2 , Irene Helenoswki 3 , Benedito A. Carneiro 1 , Young Kwang Chae 1 , William J. Gradishar 1 , Razelle Kurzrock 4 and Francis J. Giles 1 1 Division of Hematology Oncology, Northwestern Uni
Autor:
Bareng A. S. Nonyane, Sarah M. Talamantes, Eric Xie, Maya M. Lapinski, Cesar A. Santa-Maria, Kala Visvanathan, Antonio C. Wolff, Maria Cristina Figueroa Magalhães
Publikováno v:
Breast Cancer Res Treat
PURPOSE: To evaluate the relationship of circulating immune cells with recurrence and metabolic/lifestyle factors in patients with early stage breast cancer. METHODS: Patients with early stage breast cancer were identified from the electronic record
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::224666e3c9917f5e85ea1eb2a82df07a
https://europepmc.org/articles/PMC9271265/
https://europepmc.org/articles/PMC9271265/
Autor:
Haijun Zhou, Sarah M. Talamantes, Amir Behdad, Al B. Benson, Maureen Sadim, Aparna Kalyan, R. Costa, Vahid Yaghmai, Ricardo Costa, Jason B. Kaplan
Publikováno v:
Case Reports in Oncological Medicine
Case Reports in Oncological Medicine, Vol 2018 (2018)
Case Reports in Oncological Medicine, Vol 2018 (2018)
Pancreatic cancer is the fourth most common cancer death in the United States despite comprising a small percentage of the total number of cancer cases. The estimated 5-year overall survival (OS) for patients with distant metastatic disease is approx
Autor:
R.B. Costa, Francis J. Giles, R. Costa, Sarah M. Talamantes, Jonna Peterson, Benedito A. Carneiro, William J. Gradishar, Jason B. Kaplan, Irene Helenowski
Publikováno v:
Breast (Edinburgh, Scotland). 35
Purpose Cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors such as palbociclib and ribociclib are associated with distinct adverse effects (AEs) compared to other targeted therapies. This meta-analysis of clinical trials summarizes these agents' tox